Regeneron Starts Phase 3 Trial For Coronavirus Antibody Cocktail

Regeneron Pharmaceuticals has started late-stage clinical trials evaluating REGN-COV2, its investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient.